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Abstract.  Platelet-derived growth factor (PDGF) and 
transforming growth factor-~ (TGF-/~) markedly poten- 
tiate tissue repair in vivo.  In the present experiments, 
both in vitro and in vivo responses to PDGF and 
TGF-B were tested to identify mechanisms whereby 
these growth factors might each enhance the wound- 
healing response. Recombinant human PDGF B-chain 
homodimers (PDGF-BB) and TGF-B1  had identical 
dose-response curves in chemotactic assays with 
monocytes and fibroblasts as the natural proteins from 
platelets. Single applications of PDGF-BB (2 #g,  80 
pmol) and TGF-B1  (20 #g, 600 pmol) were next ap- 
plied to linear incisions in rats and each enhanced the 
strength required to disrupt the wounds at 5 d up to 
212%  of paired control wounds. Histological analysis 
of treated wounds demonstrated an in vivo chemotactic 
response of macrophages and fibroblasts to both 
PDGF-BB and to TGF-/~  1 but the response to TGF-B1 
was  significantly less than that observed with PDGF- 
BB.  Marked increases of procollagen type I were ob- 
served by immunohistochemical staining in fibroblasts 
in treated wounds during the first week. The aug- 
mented breaking strength of TGF-/31 was not observed 
2 and 3 wk after wounding. However, the positive 
influence of PDGF-BB on wound breaking strength 
persisted through the 7 wk of testing. Furthermore, 
PDGF-BB-treated wounds had persistently increased 
numbers of flbroblasts and granulation tissue through 
day 21, whereas the enhanced cellular influx in TGF- 
/31-treated wounds was not detectable beyond day 7. 
Wound macrophages and fibroblasts from PDGF-BB- 
treated wounds contained sharply increased levels of 
immunohistochemically detectable intracellular TGF-/L 
Furthermore, PDGF-BB in vitro induced a marked, 
time-dependent stimulation of TGF-/~ mRNA levels in 
cultured normal rat kidney fibroblasts.  The results sug- 
gest that TGF-/3 transiently attracts fibroblasts into the 
wound and may stimulate collagen synthesis directly. 
In contrast, PDGF is a more potent chemoattractant 
for wound macrophages and fibroblasts and may 
stimulate these cells to express endogenous growth 
factors, including TGF-/L  which, in turn, directly 
stimulate new collagen synthesis and sustained en- 
hancement of wound healing over a more prolonged 
period of time. 
p 
OLYPEPTIDE growth factors  such  as the platelet-de- 
rived growth factor (PDGF)' and transforming growth 
factor-B (TGF-B) mediate activities considered essen- 
tial for normal tissue repair processes (Deuel, 1987; Sporn 
et al.,  1987). PDGF is a potent chemoattractant for neu- 
trophils, monocytes, and fibroblasts (Deuel et al., 1982; Se- 
nior et al.,  1983; Seppii et al.,  1982) and also stimulates 
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growth factor/~; TGF-BI, recombinant-derived human transforming growth 
factor/31. 
these cells in activities of major importance in the wound- 
healing process, including the synthesis of fibronectin, col- 
lagenase,  and additional  growth factors  (i.e.,  PDGF  and 
TGF-B) (Tzeng et al., 1984, 1985; Bauer et al., 1985; Blatti 
et al., 1988; Paulsson et al., 1987; Pierce et al., 1989). TGF- 
/3 is also a potent chemotactic  agent for monocytes and fibro- 
blasts (Postlethwaite et al., 1987; Wahl et al., 1987) and in- 
duces the synthesis of extracellular matrix proteins  (Ignotz 
et al., 1987; Ignotz and Massague,  1986; Chen et al., 1987; 
Raghow et al.,  1987; Penttinen et al.,  1988; Blatti et al., 
1988;  Roberts  et al.,  1988), modulates  protease-induced 
degradation of the extracellular matrix (Lund et al.,  1987; 
Keska-Oja et al., 1988), and stimulates the synthesis of addi- 
tional growth factors (i.e., PDGF and interleukin  1) (Leof et 
al.,  1986; Wahl et al.,  1987). 
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influence wound healing was obtained when both TGF-/3 and 
PDGF were found to accelerate healing of full-thickness, in- 
cisional wounds in rats (Mustoe et al.,  1987; Pierce et al., 
1988b).  Importantly, however, PDGF and TGF-~ appear to 
operate by different mechanisms since TGF-/~ but not PDGF 
was able to reverse the deficit in wound healing induced by 
systemic glucocorticoid administration (Pierce et al., 1989). 
In this manuscript, it is shown that recombinant derived hu- 
man transforming growth factor/31  (TGF-/31) is more effec- 
tive at lower concentrations as a chemoattractant for mono- 
cytes and fibroblasts than the recombinant derived human 
B-chain (c-sis) of PDGF (PDGF-BB) in vitro, although each 
is able to attract equal numbers of  cells at optimal concentra- 
tions. However, PDGF-BB initiates a  substantially greater 
influx of  macrophages and fibroblasts into wounds than TGF- 
1. PDGF-BB continues to increase wound strength long af- 
ter the 5-7 d in which TGF-/~I produces maximal increases; 
importantly, this prolonged influence of PDGF-BB in aug- 
menting wound strength correlates directly with the demon- 
stration of enhanced TGF-/3 expression in both macrophages 
and fibroblasts, two cell types which are essential for normal 
tissue repair. The data strongly support the hypothesis that 
the persistent effects  of PDGF on wound healing may be 
mediated in part through the induction of additional endoge- 
nous growth factor activities in both fibroblasts and macro- 
phages. 
Materials and Methods 
Study Design and Model 
A full-thickness, dorsal incisional model was used, as previously described 
(Mustoe et al.,  1987).  Four to eight rats were used for each test variable. 
Paired incisions were coapted with three surgical clips and injected once 
with individual growth factors in a collagen vehicle or with collagen vehicle 
alone at the time of wounding. The wounds were excised on the specific days 
noted  and  strips perpendicular to  the paired  experimental and  control 
wounds (collagen alone) were obtained for tensometry and histologic analy- 
sis. From each rat, two to three pairs of strips were obtained for tensometry 
analysis and one to two paired samples were obtained for histologic analysis. 
Preparation of  Growth Factors in Collagen 
TGF-~I (a gift from A. Ammann, Genentech, Inc., South San Francisco, 
CA) was purified as described (Shalaby and Ammann,  1988).  Endotoxin 
levels were <0.1 rig/rag purified TGF-fll. PDGF-BB (the homodimeric prod- 
uct of the human c-sis gene) was purified to homogeneity by immunoaflinity 
chromatography (gift ofA. Tbomason, Amgen, Inc., Thousand Oaks, CA). 
PDGF-BB was shown previously to be fully equivalent in bioactivity to 
platelet-purified human PDGF-AB (Pierce et al.,  1988b).  Growth factors 
were mixed into a diluted bovine collagen suspension (Zyderm II, Collagen 
Corp. Palo Alto, CA) and were applied once only with 1 mg collagen per 
incision using a tuberculin syringe. Collagen alone (control wounds) did not 
influence the rate of healing when compared to phosphate-buffered saline. 
In in vitro experiments, both growth factors were largely released from the 
collagen vehicle within 24 h (Pierce et al., 1988b).  Histologically, the exog- 
enous collagen was no longer apparent in wounds by 4 d after surgery. 
Data Analysis 
Analysis of variance and paired t tests of breaking strength scores and of 
differences between matched experimental and control values were per- 
formed using the SAS data system (Division of Biostatistics, Washington 
University, St. Louis, MO). Percent stimulation of wound breaking strength 
in growth factor-treated samples compared to paired controls was calculated 
and analyzed using a  population r test. Breaking strength measurements 
were performed blindly on a ~nsometer (Tensometer 10; Monsanto t~o., 
St.  Louis, MO) on precoded samples. 
Histologic Analysis and lmmunoperoxidase Staining 
Matched paired samples of experimental and control wounds from each rat 
were fixed in acetic acid-ethanol (1:99, vol/vol). Paired hematoxylin- and 
eosin-stained  sections were coded and then analyzed microscopically  by two 
independent observers for the degree of cellularity (using a arbitrary scale 
from 0 to 4), for cell types within wounds, and for new granulation tissue 
within the scar.  Immunoperoxidase staining of samples was performed 
using rabbit anti-rat procollagen type I or type III monospecific  IgG fraction 
(the generous gift of K. Cutroneo, University of Vermont, Burlington, VT), 
or rabbit anti-TGF-/31 (R & D Systems, Minneapolis, MN) at appropriate 
dilutions using established methods (Pierce et al.,  1989).  Paired sections 
were incubated in primary antisera (2 p.g/ml) and then incubated with appro- 
priate dilutions of biotin-conjugated goat anti-rabbit IgG (Bethesda Re- 
search Laboratories, Gaithersburg, MD) followed by streptavidin-horserad- 
ish peroxidase (Bethesda Research Laboratories).  After development in 
3,3'-diaminobenzidine tetrahydrochloride  (Bethesda  Research  Laborato- 
ries) slides were lightly counterstained with Harris hematoxylin. Negative 
controls consisted of parallel sections incubated with comparable dilutions 
of irrelevant primary antisera. Paired wound sections were coded and ana- 
lyzed microscopically by two independent observers. In some experiments, 
another TGF-/~I specific antibody, anti-All30, was used (a girl of.l. McPher- 
son, Collagen Corp., Palo Alto, CA) (Ellingsworth et al.,  1986). 
Chemotaxis 
Chemotaxis was assayed using modified Boyden chambers (Senior et al., 
1983).  Peripheral blood mononuclear cells were separated on Ficoll-Hy- 
paque gradients from peripheral blood obtained from healthy volunteers. 
Fetal bovine ligament fibroblasts were obtained as described (Mecham et 
al., 1981). Growth factors were serially diluted in DME before use, and five 
high-power felds (fibroblasts) or grids (monocytes) were counted from 
triplicate samples. Anti-TGF-/31 (R & D Systems), a rabbit polyclonal neu- 
tralizing antibody, was premixed and serially diluted with TGF-/~I in some 
experiments to assess the specificity of the chemotactic response. 
RNA Isolation and Northern Blot Analysis 
Normal rat kidney fibroblasts (NRK, Clone 49E American Type Culture 
Collection, Rockville, MD) were maintained in DME-supplemented 10% 
fetal bovine serum (Pierce et al.,  1988b).  Cells were grown to confluency 
without a renewal of media over 6 d to ensure serum starvation. At various 
times during treatment with 50 ng/ml PDGF-BB or PDGF-BB plus l0/~g/ml 
cycloheximide (Sigma Chemical Co., St. Louis, MO) in serum-free DME, 
total cellular RNA was isolated by a modified guanidine thiocyanate proce- 
dure (Chomczynski and Sacchi,  1987).  Briefly,  cells were lysed in 4  M 
guanidine thiocyanate, extracted with water-saturated phenol/chloroform/ 
isoamyl alcohol, and the remaining RNA was precipitated twice in ethanol. 
Equal amounts (15 p,g) of RNA (estimated by absorbance at 260 nm and 
by ethidium bromide staining) were separated on standard denaturing form- 
aldehyde-agarose gels, blotted onto nitrocellulose (Schleicher and Schuell, 
Inc., Keene, NH), and prehybridized overnight as described (Pierce et al., 
1989). The blots were transferred to a fresh hybridization solution contain- 
ing 0.5  ×  10  ~ cpm/ml of a nick-translated TGF-~I probe (1.6-kb insert of 
the sp65Mur~a.s, plasmid, gift of R. Derynck, Genentech, Inc.) labeled to 
a specific activity of 8  ×  108 cpm/#g. After an overnight hybridization at 
42°C, the blot was washed and exposed to Kodak X-OMAT film (Eastman 
Kodak Co., Rochester, NY) for 4 d. Bands on the autoradiogram were quan- 
titated on a scanning laser densitometer. 
Results 
TGF-~l-induced Chemotaxis In Vitro 
Monocytes and fibroblasts were tested for chemotactic re- 
sponsiveness towards TGF-~I (Fig.  1 A). Peak chemotactic 
activity towards  both  monocytes and  fibroblasts  was  ob- 
served at 20 fM (0.5  pg/ml); anti-TGF-/~l  antiserum spe- 
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Figure 1. Chemotaxis of monocytes and fibroblasts in response to 
TGF-~  1. TGF-/31  was serially diluted and tested for chemotactic ac- 
tivity in modified Boyden chambers. (A) For monocytes, the posi- 
tive control,  10  -s M f-met-leu-phe, was  113  +  4.7 cells per high 
power grid (hpg). To test for specificity,  anti-TGF-/3  was mixed with 
TGF-/~I and serially diluted. Anti-TGF-/3  was present at 100 ng/ml 
when TGF-/31 was 10 pg/ml, Anti-TGF-/3  alone was not chemotac- 
tic and had no effect on the f-met-leu-phe response. For fibroblasts, 
the positive control, 30 ng/ml human platelet-purified PDGF-AB, 
was 57 5:3.6 cells per high power field (hpj~. (D) Fibroblasts; (o) 
monocytes; and (e) monocytes plus anti-TGF-/31. (B) Anti-TGF-/3 
abrogated the monocyte response to TGF-/31, however, it had no 
effect on the PDGF-BB-induced chemotactic response. Anti-TGF-/3 
also  had  no effect on  PDGF-BB-induced fibroblast chemotaxis 
which peaked at 30 ng/ml (data not shown). (t3) PDGF-BB; (=) 
PDGF-BB plus anti-TGF-/~l; (<3) TGF-/31; and (e) TGF-/31 plus 
anti-TGF-/31. 
cifically and fully reversed the chemotactic potential of TGF- 
/31. As reported previously, PDGF-BB was highly effective 
as a monocyte chemoattractant, with optimal activity at 0.8 
nM (20 ng/ml) (Pierce et al., 1988b). Importantly, anti-TGF- 
/31 had no effect on the PDGF-BB-generated chemotaxis on 
either monocytes (Fig. 1 B) or fibroblasts (data not shown). 
The recombinant growth factors were fully as active as TGF- 
/3 and PDGF purified from human platelets; the optimum 
migration of cells in response to TGF-/3 as a chemoattractant 
was  equal  to  that  of PDGF.  The chemotactic activity of 
PDGF is not mediated by trace contamination with TGF-/~. 
TGF-{31-induced  Augmentation of 
Wound Breaking Strength 
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Figure 2. Dose-dependent stimulation of wound breaking strength 
by TGF-/31. TGF-/31  was added in a collagen suspension once at the 
time of surgery, and wound breaking strength was tested 5 d later. 
Paired experimental and control (collagen vehicle alone) incisions 
were placed on groups of six rats for each concentration tested and 
a two-tailed, paired t-test was used to assess significance between 
matched, paired wound strips. Each dose was tested on at least two 
occasions.  100% represents  control  wound breaking  strength, 
which was  121  +  21 g (mean 5: SD). 
surgery and analyzed the breaking strength of wounds 5 d 
later (Fig. 2). 2 #g TGF-~ per incision maximally increased 
the strength required to disrupt incisional wounds (212% of 
paired  controls, p  <  0.005).  Peak  stimulation  of wound 
breaking strength by TGF-/31 was observed 5 and 7 d after 
wounding; the wound healing was accelerated by 2-3 d over 
the first week relative to control wounds (Fig. 3 A). The func- 
tional activity of TGF-/~I  was  identical to TGF-/3 purified 
from human platelets in time course, dose response, and in 
optimum  enhancement of healing  (Mustoe  et al.,  1987). 
Significantly, no evidence of delayed reepithelialization was 
found in TGF-/31-treated  wounds. 
Differences between TGF-{31-  and PDGF-BB-induced 
Wound Repair 
The enhancement of wound healing after single applications 
of optimal  concentrations  of TGF-fll  or  PDGF-BB  were 
compared for 49 d (Fig. 3 C). Striking differences were ob- 
served; compared to PDGF-BB, TGF-/31 generally enhanced 
wound strength to a greater degree 5 d after wounding while 
at  7  d  both  growth  factors consistently increased wound 
breaking strength equally, averaging  150-200%  of paired 
control values (Fig.  3 A). However, TGF-/31 no longer ac- 
celerated healing beyond the initial 2-wk period. PDGF-BB 
continued to significantly enhance the breaking strength of 
treated wounds through the 49 d under study (Fig. 3 B). The 
healing of PDGF-BB-treated wounds was accelerated 28 d 
after wounding by 5-10 d compared to paired controls; the 
differences between PDGF-BB-treated and control wounds 
amounted to ~,15%  of the total wound breaking strength of 
the treated wounds between 28 and 49 d (Fig. 3 B). No evi- 
dence  of  hypertrophic  scar  formation  was  observed  in 
PDGF-BB-treated wounds (see histologic analysis below). 
In other experiments, suboptimal doses of PDGF-BB and 
TGF-/ffl were tested in combination to identify potential addi- 
tive, synergistic, or antagonistic effects. An additive effect of 
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Figure 3. Pair incisional wounds received either growth factor (2/~g TGF-/~I, 20/~g PDGF-BB) or collagen alone on the day of surgery, 
and 11-14 paired growth factor-treated and control strips were harvested on each day indicated for maximum breaking strength determina- 
tions (mean +  SEM). A two-tailed, paired t-test was used to calculate the P value. (A) Acceleration of healing induced by PDGF-BB or 
TGF-/31 during the first week after surgery. (B) Effects of growth factors applied at the time of surgery through 49 d (PDGF-BB) or 35 d 
(TGF-~I). (e) PDGF-BB; (o) control;  (m) TGF-/31; ([]) control.  (C) Differences in breaking strength measurements between growth 
factor-treated and paired control wounds, calculated from the values presented in A and B. (m) PDGF-BB; (t2) TGF-BI. 
suboptimal concentrations of both growth factors was ob- 
served on day 7  (data not shown) but, by day 21, only the 
PDGF-induced  augmentation  of wound  healing  was  ob- 
served. When added together at optimal concentrations, the 
breaking strength required to disrupt the wounds was pre- 
cisely that expected for PDGF-BB or TGF-~I alone at day 
7, and for PDGF-BB alone at day 21  (data not shown). 
Analysis of Cellular Influx into Wounds 
The cellular influx into TGF-/31-treated wounds was analyzed 
and quantitatively compared with matched, paired control 
wounds  (Table  I).  Increased  macrophage  and  fibroblast 
influx occurred within 3-5 d of wounding in TGF-~l-treated 
(2 #g) wounds (p < 0.01). This enhancement of cell migration 
was qualitatively and quantitatively decreased relative to the 
enhancement found previously in PDGF-BB-treated wounds 
(Pierce et al.,  1988b); PDGF-BB induced a large increase 
in the influx of neutrophils on days 1 and 2 and of macro- 
phages and fibroblasts on days 3-5. The PDGF-BB enhance- 
ment of cell migration was substantially above the cellular 
influxes induced  in  TGF-~l-treated wounds  (Fig.  4).  The 
influx of cells in response to PDGF-BB in vivo correlated 
well with  chemotactic responses in vitro.  Wounds treated 
with lower concentrations of TGF-~I demonstrated less of a 
cellular influx, in contrast to the more potent effects observed 
at lower concentrations of TGF-~I in the chemotaxis assay. 
TGF-~I, thus, is nearly 40,000-fold more potent on a mole/ 
Table I.  Quantitative  Analysis of Cellular Influx in PDGF-BB- or TGF-~l-treated Wounds* 
Difference in 
Days  Growth  Difference  granulation  Predominant 
after wounding  factor  in cellularity~  t  tissue¢  cell type 
I-2  TGF-/~I  +0.08  +  0.25  Neutrophil, macrophage 
3-5  TGF-/~I  +0.64  -I- 0.22§  Macrophage,  fibroblast 
7-10  TGF-/~I  +0.12  +  0.26  Fibroblast 
14  TGF-/~I  +0.14  +  0.21  +0.18  +  0.38  Fibroblast 
21  TGF-/31  +0.08  -I- 0.26  +0.17  +  0.29  Fibroblast 
14-21  PDGF-BB  +0.70  +  0.2411  +0.75  +  0.2611  Fibroblast 
28-49  PDGF-BB  -0.36  -I- 0.24  -0.36  +  0.37  Fibroblast 
* Growth factor-treated  and paired control wound sections were harvested on the days indicated and processed,  embedded, and stained with hematoxylin and eo- 
sin. They were coded and blindly rated by two individuals on a scale from 0-4 for cellularity and new granulation tissue within the scar (from day  14 onward). 
TGF-/~I (2/zg) or PDGF-BB (20/~g) were applied to incisions once on the day of wounding.  A score of 0 represented baseline cellularity in unwounded dermis 
and no granulation tissue. Cellularity  in PDGF-BB-treated wounds during the first 2 wk after wounding was previously reporbed, and was significantly increased 
above controls  from days  i-14 (Pierce et al.,  1988b). 
:~ The mean (+SEM) difference of scores between growth factor-treated  and paired control wounds was calculated for 6-12 sections per group. Median values 
were nearly identical to means,  indicating the data were normally distributed.  Granulation tissue (scar) was assessed from day  14 on wounds. 
§ P <  0.01,  two-tailed,  paired t-test. 
II P <  0.02. 
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activity; in vivo, TGF-~ is <10-fold more active on a mole/ 
mole basis. More importantly, PDGF-BB at optimal concen- 
trations induces a greater influx of cells into wounds in vivo 
than does TGF-~I. The chemotactic potential of PDGF-BB 
on wound cellularity was sustained through 21 d in contrast 
to the transient effects of TGF-/Yl. The sustained increase in 
cellular influx correlated directly with increased granulation 
tissue at this time and with the persistent increases in break- 
ing strength in PDGF-treated wounds (Fig. 5). Interestingly, 
during the second month after wounding, the cellularity and 
granulation tissue content of PDGF-BB-treated wounds, in 
contrast to the wound breaking strength, was less than that 
found in paired controls. This time-dependent trend in cel- 
lularity and granulation tissue was reproducible, but was not 
statistically significant. 
Analysis of  Procollagen 7)TJes I and III in Wounds 
The formation of new collagen in wounds is considered the 
most important correlate with developing strength within the 
wound (Levenson et al., 1968; Madden and Peacock, 1968). 
Immunohistochemical analyses of procollagen type I  and 
type III content in growth factor-treated and control wounds 
were performed.  In each group,  although the numbers of 
fibroblasts per high-power field were substantially greater in 
the  growth  factor-treated groups,  the  proportions  of the 
fibroblasts (~40-50%) containing procollagen type I 3-7 d 
after wounding were similar. The results suggested that in 
wounds not treated with growth factors, an adequate endoge- 
nous signal is provided to induce those fibroblasts present to 
generate  new collagen.  The  enhanced healing,  therefore, 
correlated directly with the significant increase in the num- 
bers of fibroblasts attracted into wounds treated with PDGF- 
BB or TGF-/~I, which in turn accounted for the substantial 
increase in total procollagen type I observed relative to the 
content of procollagen type I  in matched control wounds 
(Fig. 6). No differences in percentage staining or staining in- 
tensity of  procollagen type I or III were observed in compari- 
sons of TGF-~I- and PDGF-BB-treated. wounds at days 3-7. 
Fewer than 3 % of the wound fibroblasts were shown to have 
detectable levels of intracellular procollagen type III in either 
growth factor-treated or control wounds (data not shown). 
Analysis of  lntraceUular TGF-(3 in Wounds 
Since procollagen synthesis is perhaps the major contributor 
to  increased  wound  strength,  the  prolonged  influence of 
PDGF-BB is in apparent conflict with the inability of PDGF 
to,directly promote procollagen synthesis in fibroblasts in 
vitro and in wounds from glucocorticoid-treated experimen- 
tal  animals  (Roberts  et  al.,  1986;  Pierce  et  al.,  1989). 
PDGF-BB was shown to induce expression of TGF-/~ in a 
monocyte line (Pierce et al., 1989) and thus may act through 
the monocyte/macrophage to provide TGF-/~I for stimulation 
of procollagen synthesis in fibroblasts. However, the macro- 
phage is not prominent in tissue sections of treated wounds 
after 7-10  d (Pierce et al.,  1988b),  suggesting that PDGF 
might act at the level of the fibroblast in 7-10-d wounds over 
and  above  its  influence on  the  macrophage  early  in  the 
wound-healing process. Sections from 2, 4, and 7 d PDGF- 
BB-treated and paired control wounds were analyzed with a 
monospecific anti-TGF-~ antiserum.  Specific intracellular 
staining of TGF-/~ was identified in normal wounds. Remark- 
ably, increased numbers of macrophages (days 2 and 4) and 
fibroblasts (days 4  and 7)  containing intracellular TGF-/~ 
were  found in  PDGF-BB-treated  wounds  (Fig.  7).  Anti- 
A1/30, a second specific anti-TGF-~ antisera, was used to 
confirm this result.  The results indicated that PDGF was 
capable of inducing increased intracellular TGF-~ levels in 
vivo, both in the macrophage and in the fibroblast. A similar 
analysis of TGF-~l-treated wounds with anti-TGF-/~ was not 
productive due to background staining. However, when quies- 
cent NRK cells were stimulated in vitro by 50 ng/ml PDGF- 
BB, a marked time-dependent increase in TGF-fl mRNA was 
observed (•10-fold  increase, Fig. 8), confirming that the in- 
creased intracellular TGF-~ observed in wound fibroblasts 
can arise from a direct stimulatory action by PDGF and that 
the increase in procollagen type I may arise from the subse- 
quent autocrine stimulatory influence of newly synthesized 
TGF-t31. 
Discussion 
Direct evidence supports both PDGF and TGF-fl as impor- 
tant transducers of tissue repair mechanisms (Deuel,  1987; 
Pierce and Deuel, 1989).  PDGF was the frst growth factor 
shown  to  be  chemotactic  for  monocytes and  neutrophils 
(Deuel et al.,  1982;  Senior et al.,  1983);  recently TGF-/~ 
purified  from  platelets  was  also  found  to  be  a  potent 
chemotactic protein (Postlethwaite et al., 1987; Wahl et al., 
1987).  Both growth factors are released by degranulating 
platelets at the initiation of wound repair (Deuel, 1987; As- 
soian and Sporn, 1986), and both growth factors may be ex- 
pressed by cells active in inflammation and repair, producing 
an augmented cascade of activities leading to increased mac- 
rophage  and fibroblast influx.  The  increased numbers of 
these cells in PDGF or TGF-fl-treated wounds directly sup- 
port this hypothesis. Both PDGF- and TGF-~-like growth 
factors are present in monocytes/macrophages (Derynck et 
al.,  1985;  Shimokado et al.,  1985;  Martinet et al.,  1986; 
Cheng et al., 1987; Assoian et al., 1987; Fig. 7), which are 
normally directed to sites of wounds within the first 24--48 h 
(Liebovich and Ross, 1975; Hunt et al., 1983; Pierce et al., 
1988b).  Activated macrophages also represent a significant 
source of other cytokines which may function in tissue re- 
pair, including interleukin 1 and tumor necrosis factor (Na- 
than,  1987; Rappolee et al.,  1988). 
The present investigations firmly establish that PDGF-BB 
and TGF-/~I function identically to their natural counterparts 
purified from human platelets in chemotactic assays in vitro 
and in the enhancement of breaking strength in incisional 
wounds in vivo. Both PDGF-BB and TGF-/~I were incapable 
of synergistic effects when analyzed at suboptimal or optimal 
concentrations, suggesting that procollagen synthesis, which 
best correlates with breaking strength in healing wounds, is 
rate limiting. Previous data obtained in vitro indicated that 
PDGF  cannot  directly  increase  procollagen  synthesis  in 
fibroblasts (Roberts et al., 1986), in contrast to TGF-~ (Rossi 
et  al.,  1988).  However,  in  the  present  experiments  the 
marked increase in the numbers of fibroblasts attracted to 
both PDGF-BB- and TGF-/~l-treated  wounds were equally 
intense in procollagen type I immunostaining, implying that, 
although PDGF-treated wounds have markedly increased in 
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healing wounds only indirectly. The indirect effect of PDGF 
on fibroblast procollagen synthesis  was further tested  at a 
time when the influence of PDGF-BB had extended well be- 
yond the period of macrophage influx into wounds. Wounds 
treated  with  PDGF-BB  continued  to  manifest  increased 
strength above paired controls through day 49 and contained 
significantly  greater  numbers of fibroblasts  and  increased 
granulation  tissue within  the wounds through  day 21.  Be- 
cause PDGF-BB induces and sharply enhances the expres- 
sion of the TGF-/3 gene in quiescent macrophages and  in 
fibroblasts  in vitro (Van Oberrghen-Schilling,  1988, Pierce 
et al.,  1989;  Fig.  8),  one distinction  between TGF-~I  and 
PDGF-BB may be the initial requirement of the macrophage 
and subsequently the fibroblast for the activation of endoge- 
nous growth factors such as TGF-/~ to transduce the external 
signal of PDGF-BB. Furthermore, the persistent stimulation 
of the fibroblasts attracted to the wounds through  the potent 
chemotactic potential  of PDGF-BB may lead to new expres- 
sion of  endogenous TGF-~ within wound fibroblasts and sub- 
sequent expression of procoUagen type I. This hypothesis is 
consistent with the induction  of TGF-/3 mRNA synthesis ob- 
served in vitro in PDGF-treated fibroblasts.  Other possible 
mechanisms  which  may  be  responsible  for  the  observed 
prolonged effect of  PDGF are currently under study, and may 
include the regulation  of collagenase synthesis (Bauer et al., 
1985),  which is required for wound remodeling.  Although 
TGF-/3 also stimulates  expression  of "IGF-/3 in fibroblasts in 
vitro (Van Oberrghen-Schilling,  1988), the transient cellular 
influx observed in TGF-/31-treated wounds may not provide 
an adequate stimulus for the initiation of a cascade effect, as 
observed in PDGF-BB-treated wounds. 
PDGF also  sharply  stimulates  fibroblast expression  of 
PDGF-AA chain (Paulsson et al.,  1987; Pierce G. E, V. R. 
Masakowski, B. Tong, and T. E  Deuel, manuscript submit- 
ted for publication).  PDGF, thus,  may activate an autocrine 
loop to effect a positively regulated cascade of growth factor 
activities during normal tissue repair. Finding increased num- 
bers of macrophages and fibroblasts  which contain  TGF-~ 
in PDGF-BB-treated wounds offers strong support to this hy- 
pothesis. Despite the ability of  epidermal growth factor to in- 
duce  PDGF-AA  in  cultured  fibroblasts  (Paulsson  et  al., 
1987), a single application  of epidermal growth factor does 
not recruit cells into incisional wounds and does not augment 
wound breaking  strength  (unpublished  observations). Thus, 
the unique inductive and chemotactic effects of PDGF-BB and 
TGF-/31 in vivo are not generalized  activities  mimicked by 
other growth factors. 
Important in vivo roles of TGF-/~ and PDGF may also in- 
clude the regulation  of procollagen  type I, thrombospondin, 
fibronectin,  collagenase,  glycosaminoglycan, and fibronec- 
tin  receptor  synthesis  by  TGF-/3 (Ignotz  and  Massague, 
1986; Ignotz et al.,  1987; Raghow et al.,  1987; Chen et al., 
1987; Pentinnen et al.,  1988; Chua et al.,  1985; Edwards et 
The Journal of Cell Biology,  Volume  109, 1989  4-34 Figure 4. Cellular influx into 2/~g TGF- 
El-treated (A and C), or control (B and 
D) incisions 3 d after wounding. Note 
the  increased  influx  of  mononuclear 
cells (primarily macrophages and fibro- 
blasts)  throughout  the  TGF-Bl-treated 
wounds in these hematoxylin- and eosin- 
stained sections. New granulation tissue 
(arrowheads, A and B) and vessel for- 
mation (arrowheads,  C and D) are oc- 
curring  at the  base  of TGF-~l-treated 
wounds, compared to the paired control. 
PDGF-BB-treated wounds consistently 
demonstrated a greater  influx of mac- 
rophages  and  fibroblasts  at  this  time 
(Pierce  et al.,  1988b), in comparison 
with TGF-Bl-treated wounds. Bars: (A 
and B) 200/~m;  (C and D) 20 #m. 
al.,  1987;  Roberts  et  al.,  1988;  Bassols  and  Massague, 
1988), and fibronectin and collagenase production by PDGF 
(Bauer et al.,  1985; Chua et al.,  1985; Blatti et al.,  1988); 
all are essential time-dependent activities for normal tissue 
repair (Pierce and Deuel, 1989). The unique mechanisms of 
action and time course of activities we have identified for 
PDGF and TGF-B suggest each of these growth factors may 
find  optimal  therapeutic  application  in  specific  types  of 
wounds in man. 
The linear incision model represents an important tool for 
the evaluation of tissue repair activities regulated by poly- 
peptide growth factors. Wound healing models using dead 
space chambers or polyvinyl sponges may induce a foreign 
body inflammatory response replete with foreign body giant 
cells that is significantly delayed in onset compared to the 
normal wound inflammatory response (Sporn et al.,  1983; 
Sprugel et al.,  1987; Grotendorst et al.,  1985; Davidson et 
al.,  1985). Diffusion of factors and the failure of cells to in- 
teract with normal substrates further limit interpretation of 
results  from  these  models.  However,  contents  of wound 
chambers  are  readily accessible to  extensive biochemical 
analyses,  an advantage  for analyzing  extracellular matrix 
composition.  Full-thickness biopsy models which test the 
acceleration of wound closure due to contraction are also not 
directly applicable to human wounds since, in man, wound 
contraction is of lesser importance. In contrast, the linear in- 
cision model corresponds precisely to the physiologically 
relevant time-dependent cellular and extracellular matrix ac- 
tivities required for normal tissue repair (Levenson et al., 
1968; Madden and Peacock,  1968; Ross,  1968). 
Importantly,  the elucidation of the  roles of PDGF and 
TGF-B in normal tissue repair provides valuable insights into 
Pierce et al.  Unique PDGF- and TGF-~-induced Tissue Repair Activities  435 Figure 5. Appearance of wounds 3 wk after treatment with 20/~g PDGF-BB (A and C), or vehicle alone (B and D). Representative Mas- 
son-trichrome stained sections show the persistent, increased granulation tissue and neovascularization  and fibroblast  content within PDGF- 
BB-treated wounds, compared to control wounds at this time (arrowheads).  The cellularity and granulation tissue content of'I'GF-B  1-treated 
wounds was identical to control wounds at this time. Quantitative analysis was performed using paired, growth factor-treated and control 
wounds.  Bars: (A and B)  100/~m;  (C and D) 50/~m. Figure 6.  Procollagen type I immunochemical staining of fibroblasts from PDGF-BB (20/~g; A and C) or matched control wounds (B 
and D) 7 d after wounding. Similar proportions of fibroblasts contained intracellular procollagen type I, from all wounds. However, the 
increased fibroblastic influx in PDGF-BB-treated wounds resulted in an overall significant increase in procollagen type I content in the 
growth factor-treated wounds and this increase correlated with the observed increase in wound breaking strength. Results using TGF-/31- 
treated wounds were similar to those observed using PDGF-BB. Bars: (,4 and B)  100/~m;  (C and D) 50 #m. Figure 7. In situ localization of  TGF-B  in in- 
cisional wounds treated with 20/zg PDGF- 
BB (A) or controls (B). Paired wounds were 
harvested on days 2, 4, and 7, and processed 
for immunostaining using anti-TGF-/51 an- 
tiserum.  Note the increased proportion of 
cells  containing  intracellular  TGF-B  in 
PDGF-BB-treated  wounds compared  to 
matched control wounds on day 7.  These 
wounds  were  photographed  immediately 
adjacent to the panniculus carnosis muscle 
layer, in the dermis.  Similar results were 
obtained on days 2 and 4. Bars, 50 tim. 
their activities  in  pathological  states.  PDGF-Iike proteins 
have been observed in pulmonary fibrosis and are thought to 
be synthesized by activated alveolar macrophages (Martinet 
et al.,  1987; Deuel and Senior, 1987). PDGF has also been 
found associated with atherosclerotic plaques, is made and 
secreted by  aortic  smooth  muscle  cells  and  vascular  en- 
dothelial cells, and has been found in the normal arterial wall 
(Jaye et al.,  1985; Collins et al.,  1987; Barrett and Benditt, 
1988;  Majesky et al.,  1988).  Although a  causal  role  for 
PDGF in pulmonary fibrosis or in the atherosclerotic pro- 
cess has not been established, the present results obtained 
with PDGF and TGF-/3 suggest these growth factors may be 
active in these microenvironments. Further elucidation of 
the mechanisms of action of PDGF and TGF-# should pro- 
vide important insights into their roles in normal and com- 
promised tissue  repair activities, as  well as  their roles in 
fibrotic processes. 
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